Return to Listing

6 result(s) for Taxotere

PI Name Protocol # Title
Tomasz Beer IRB00005688 A Phase II study of MAOA inhibitor plus docetaxel in patients receiving and progressing on docetaxel therapy
Tomasz Beer IRB00010479 A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
Christopher Ryan IRB00010659 A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator’s Choice in Subjects with Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy
Jeremy Cetnar IRB00011046 S1400, Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Khaled Tolba IRB00011740 TIGER-3: A Phase 3, Open-label, Multicenter, Randomized Study of Oral Rociletinib (CO 1686) Monotherapy Versus Single-agent Cytotoxic Chemotherapy in Patients with Mutant EGFR Non-small Cell Lung Cancer (NSCLC) after Failure of at Least 1 Previous EGFR-directed Tyrosine Kinase Inhibitor (TKI) and Platinum-doublet Chemotherapy
Khaled Tolba IRB00011967 An open label, multicenter, phase 2 study to determine the safety and efficacy of BIND-014 (docetaxel nanoparticles for injectable suspension) as a second-line therapy for patients with KRAS mutation positive or Squamous cell non-small cell lung cancer

You may also qualify for Phase 1 Program trials.

For more information:
Call: 503-494-1080